trending Market Intelligence /marketintelligence/en/news-insights/trending/1z0KlOFwif12xztR4x7XDA2 content
Log in to other products

Login to Market Intelligence Platform


Looking for more?

Contact Us

Request a Demo

You're one step closer to unlocking our suite of comprehensive and robust tools.

Fill out the form so we can connect you to the right person.

If your company has a current subscription with S&P Global Market Intelligence, you can register as a new user for access to the platform(s) covered by your license at Market Intelligence platform or S&P Capital IQ.

  • First Name*
  • Last Name*
  • Business Email *
  • Phone *
  • Company Name *
  • City *
  • We generated a verification code for you

  • Enter verification Code here*

* Required

In This List

Japan expands use of Chugai's cancer diagnostic test

S&P Global Market Intelligence

Cannabis: Hashing Out a Budding Industry


IFRS 9 Impairment How It Impacts Your Corporation And How We Can Help

The Market Intelligence Platform

Japan expands use of Chugai's cancer diagnostic test

Chugai Pharmaceutical Co. Ltd. said the Japanese Ministry of Health, Labor and Welfare approved the expanded use of FoundationOne CDx to identify patients who would be eligible for treatment with Roche Holding AG's Rozlytrek.

The diagnostic test can be used to detect genetic mutations in any solid tumor type and is now approved to identify patients whose non-small cell lung cancer expresses the ROS1 genetic abnormality. ROS1 is a biomarker for locally advanced or metastatic NSCLC and is found in 1% to 2% of patients.

Roche's Rozlytrek is meant for patients who have the ROS1 genetic abnormality.

Chugai filed an application in March seeking approval for the indication. FoundationOne CDx was developed by Foundation Medicine Inc., which licensed the product to Roche, the parent of Chugai Pharmaceutical.

The diagnostic test was approved in Japan in 2018 and in the U.S. in 2017 for cancer diagnosis.